Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases

Novartis Foundation Symposium

Volumn 248, Issue , 2002, Pages 254-276

  Disse, Bernd ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; EXPECTORANT AGENT; RESPIRATORY TRACT AGENT;

CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG SCREENING; EXOCYTOSIS; HUMAN; LUNG FUNCTION TEST; METHODOLOGY; MUCUS; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; RESPIRATORY TRACT DISEASE; REVIEW; SAFETY; SECRETION; SMOKING CESSATION; STANDARD; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS; DRUG EVALUATION; EXOCYTOSIS; EXPECTORANTS; HUMANS; MUCUS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RESPIRATORY SYSTEM AGENTS; RESPIRATORY TRACT DISEASES; SAFETY; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 0038349999     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (31)

1. Anthonisen NR, Manfreda J, Warren CP, Hersfield ES, Harding GK, Nelson NA 1987 Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106:196-204
2. Boyd EM 1972 Respiratory tract fluid. Charles C Thomas Publisher, Springfield, Illinois, USA
3. Carone M, Jones PW 2000 Health status 'quality of life'. In: Donner CF, Decramer M (eds) Pulmonary rehabilitation. European Respiratory Society, Sheffield, vol 13, p 22-35
4. Committee for Proprietary Medicinal Products (CPMP) 1999 Points to consider on clinical investigation of medicinal products in the chronic obstructive pulmonary disease (COPD). CPMP/EWP/562/98
5. Decramer M, Dekhuijzen PN, Troosters T et al 2001 The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial committee. Eur Respir J 17:329-326
6. Disse B 2001 Novel perspectives in anticholinergic therapy. In: Zaagsma J, Meurs H, Roffel ADF (eds) Muscarinic receptors in airways diseases, progress in inflammation research, Birkhäuser Verlag, Basel p 221-258
7. Disse B, Witek TJ 2001 Anticholinergics: Tiotropium. In: Hansel TT, Barnes PJ (eds) New drugs for asthma, allergy and COPD. Prog Respir Res Vol 31, Karger, Basel, p 72-76
8. Fahy JV, Liu J, Wong H, Boushey HA 1994 Analysis of cellular and biochemical constituents of induced sputum after allergen challenge: a method for studying allergic airway inflammation. J Allergy Clin Immunol 93:1031-1039
9. FDA Advisory Committee 2002, January 17, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Pulmonary and Allergy Drug Products, (HFD-570) Backgrounder for sNDA 21-077 - Advair Diskus 250/50, Advair Diskus 500 http:// www.fda.gov/ohrms/dockets/ac/acmenu.htm
10. Germouty J, Jirou-Najou JL 1987 Clinical efficacy of ambroxol in the treatment of bronchial stasis. Clinical trial in 120 patients at two different doses. Respiration 51:S37-S41
11. ICH 1995 Topic E1a population exposure: the extent of population exposure to assess clinical safety. ICH 375/95
12. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ 1998 Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 53:91-95
13. Johnson M, Hagan GWE 2001 Long acting ß2-agonists. In: Hansel TT, Barnes PJ (eds) New drugs for asthma, allergy and COPD. Prog Respir Res Vol 31, Karger, Basel p 60-63
14. Jones PW, Quirk FH, Baveystock CM, Littlejohns P 1992 A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145:1321-1327
15. Maestrelli P, Richeldi L, Moretti M, Fabbri LM 2001 Analysis of sputum in COPD. Thorax 56:420-422
16. Mahler DA, Weinberg DH, Wells CK, Feinstein AR 1984 The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85:751-758
17. McEvoy CE, Niewoehner DE 2000 Corticosteroids in chronic obstructive pulmonary disease. Clinical benefits and risks. Clin Chest Med 21:739-752
18. Niewoehner DE, Erbland ML, Deupree RH et al 1999 Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 340:1941-1947
19. Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE 1997 The use of induced sputum to investigate airway inflammation. Thorax 52:498-501
20. Pauwels RA, Buist AS, Calverly PMA, Jenkins CR, Hurd SS 2001 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/ WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Crit Care Med 163:1256-1276
21. Petty TL 1990 The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 97:75-83
22. Physicians Desk Reference 2002 56 edition, Medical Economics Company, Montvale NJ, USA (Pulmozyme p 1426-1428)
23. Poole PJ, Black PN 2001 Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Brit Med J 322:1271-1274
24. Rubin BK, Ramirez O, Ohar JA 1996 Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 109:348-352
25. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS 2000 Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 161:381-390
26. Saint S, Bent S, Vittinghoff E, Grady D 1995 Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 273:957-960
27. Stockley RA, O'Brien C, Pye A, Hill SL 2000 Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117:1638-1645
28. Tamaoki J, Chiyotani A, Kobayashi K, Sakai N, Kanemura T, Takizawa T 1992 Effect of indomethacine on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis or bronchiectasis. Am Rev Respir Dis 145:548-552
29. Tamaoki J, Chiyotani A, Tagaya E, Sakai N, Konno K 1994 Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax 49:545-548
30. Torphy JT, Compton CH, Marks MJ, Sturton, G 2001 Phosphodiesterase 4 inhibitors. In: Hansel TT, Barnes PJ (eds) New drugs for asthma, allergy and COPD. Prog Respir Res Vol 31, Karger, Basel p 321-325
31. Woolhouse IS, Hill SL, Stockley RA 2001 Symptom resolution assessed using a patient directed diary card during treatment of acute exacerbations of chronic bronchitis. Thorax 56:947-953